Performance-Enhancing Drugs in Sports: Types, Effects, and Why They're Banned

A History of Doping in Sport

The use of substances to enhance athletic performance predates modern sport. Ancient Greek Olympians reportedly consumed herbal concoctions and animal organs believed to convey strength or speed. Nineteenth-century cyclists used combinations of caffeine, cocaine, strychnine, and alcohol on multi-day stage races, with several deaths attributed to these cocktails. When the modern Olympics were revived in 1896, doping was already embedded in professional cycling and track athletics.

The mid-twentieth century brought industrialized doping. Soviet athletes began systematic anabolic steroid programs in the 1950s, and word spread rapidly. By the 1960s, amphetamine use was so widespread in cycling that British cyclist Tommy Simpson died on the slopes of Mont Ventoux during the 1967 Tour de France with amphetamines in his bloodstream. The International Olympic Committee established the first banned substances list in 1967 and conducted the first Olympic drug tests at the 1968 Mexico City Games. The decades since have been defined by an ongoing escalation between pharmacological innovation and detection science.

Anabolic-Androgenic Steroids

Anabolic-androgenic steroids (AAS) are synthetic derivatives of testosterone that promote protein synthesis in skeletal muscle (the anabolic effect) and stimulate the development of male secondary sex characteristics (the androgenic effect). They are the most widely abused category of doping substances across strength and power sports, with documented use in weightlifting, sprinting, throwing events, and team sports including football and baseball.

AAS increase muscle mass and strength by binding to androgen receptors in muscle cells, activating genes that upregulate protein synthesis and inhibit the protein-degrading effects of cortisol. They also increase red blood cell production, which improves oxygen delivery and endurance. The performance benefits are substantial: research in trained athletes demonstrates that AAS use combined with resistance training produces significantly greater gains in muscle mass and strength than training alone, even at relatively low doses.

The health consequences are extensive and well-documented. Cardiovascular effects include left ventricular hypertrophy (enlargement of the heart's main pumping chamber), reduced HDL ("good") cholesterol and elevated LDL ("bad") cholesterol, hypertension, and dramatically increased risk of sudden cardiac death. Former AAS users show higher rates of coronary artery disease even decades after stopping use. Endocrine effects include testicular atrophy, reduced testosterone production after cycling off, infertility, and gynecomastia (breast tissue development in men). Psychiatric effects include increased aggression, mood swings, depression during withdrawal, and in some users, a persistent anabolic steroid-induced hypogonadism requiring lifelong hormone replacement therapy.

Erythropoietin and Blood Doping

Erythropoietin (EPO) is a hormone produced by the kidneys that stimulates the bone marrow to produce red blood cells. Synthetic recombinant EPO, developed in the 1980s as a treatment for anemia in kidney disease patients, was rapidly adopted by endurance athletes because elevated red blood cell mass dramatically increases the blood's oxygen-carrying capacity, directly boosting VO2 max and endurance performance. The effect is substantial: studies show that EPO can improve endurance performance by 3–7 percent, an enormous margin in sports where hundredths of seconds determine medals.

Blood doping — either transfusing stored autologous (one's own) blood or donor blood before competition — achieves the same hemoglobin elevation without any detectable drug. Both EPO and blood transfusions are banned under the WADA code. EPO abuse was epidemic in professional cycling through the 1990s and early 2000s; retrospective studies suggest that during this era, upward of 80 percent of Tour de France peloton riders may have been using EPO, and researchers have attributed unexplained deaths of young cyclists during that period to EPO-induced blood thickening that increased clot risk during rest.

Detection of EPO evolved from indirect markers (abnormally high hematocrit values, unusual blood parameter patterns) to direct immunoassay tests that can distinguish natural EPO from synthetic variants based on subtle glycosylation differences. The Athlete Biological Passport (ABP), introduced by WADA in 2008, takes a longitudinal approach — monitoring each athlete's blood parameters over time to detect statistically improbable changes that suggest manipulation, even when no specific substance is detected.

Human Growth Hormone and Peptide Hormones

Human growth hormone (HGH) promotes the growth of muscle and connective tissue, stimulates fat metabolism, and is believed to accelerate recovery from injury. Its abuse in sport, particularly in combination with AAS and EPO, became widespread in the 1990s and 2000s. Because it naturally varies widely between individuals and fluctuates dramatically throughout the day, detecting synthetic HGH administration was technically challenging for many years.

Current testing uses two complementary methods: the isoform differential immunoassay (detecting the ratio of naturally occurring GH variants, which is disturbed by synthetic administration) and the biomarker test (measuring IGF-1 and the bone marker P-III-NP, which are elevated when HGH is administered). Insulin-like growth factor 1 (IGF-1), a downstream mediator of GH action, is also abused directly, as are a range of synthetic peptides — such as GHRP-2, GHRP-6, and CJC-1295 — that stimulate the pituitary to release growth hormone. These peptides present an ongoing detection challenge because they are rapidly cleared from the body and exist in tiny concentrations.

Stimulants, Beta-2 Agonists, and Beta Blockers

Stimulants including amphetamines, cocaine, methylphenidate, and modafinil increase alertness, reduce fatigue perception, and in some cases increase aggression and pain tolerance. Their use is most prevalent in high-intensity, short-duration sports and in team sports where recovery of focus through a long game is important. The risks include cardiovascular events, psychological dependence, and in high doses, hyperthermia and death.

Beta-2 agonists, primarily used as bronchodilators in asthma treatment, also have anabolic properties at high systemic doses. Clenbuterol, technically a beta-2 agonist, became notorious as a fat-loss and muscle-preservation drug used in endurance and aesthetic sports. Athletes with genuine asthma requiring inhaled beta-2 agonists can obtain therapeutic use exemptions (TUEs), a system that has been criticized for potential abuse but which WADA continues to defend as necessary to protect athletes with legitimate medical conditions.

Beta blockers reduce heart rate and physical tremor by blocking the effects of adrenaline. In precision sports requiring steady nerves — archery, shooting, golf, snooker — they provide a meaningful performance advantage. They are banned specifically in these sports but permitted in endurance sports where their heart-rate-lowering effect would actually impair performance.

The Anti-Doping System: WADA and Its Limits

The World Anti-Doping Agency (WADA), established in 1999, coordinates global anti-doping efforts through the World Anti-Doping Code — a harmonized framework adopted by sports federations and national Olympic committees worldwide. The Code prohibits substances and methods that meet at least two of three criteria: they enhance performance, they carry health risks, or they violate the spirit of sport. Testing includes both in-competition and out-of-competition testing (the latter being critical for substances like EPO that are typically administered in training), and athletes are required to provide their whereabouts to enable unannounced testing.

The system has significant limitations. No-notice testing is resource-intensive and financially dependent on national anti-doping organizations that vary enormously in funding and capacity. Some national programs have historically protected their athletes from testing or failed to process positive samples — the McLaren Report in 2016 documented a Russian state-sponsored doping program that manipulated urine samples at the Sochi Olympics with the direct involvement of the FSB secret service. Designer drugs — novel compounds synthesized to evade existing tests — create a perpetual detection lag. And microdosing strategies, which keep drug concentrations below detection limits, make many substances effectively undetectable with current technology.

Despite these challenges, anti-doping science continues to advance. Next-generation sequencing approaches are being explored for detecting gene doping — the use of gene therapy techniques to enhance muscle growth or oxygen delivery. Longitudinal biological passport monitoring is catching athletes who previously evaded direct testing. And the long-term storage of samples (WADA requires samples be stored for ten years) allows retrospective testing with new methods, producing the wave of disqualifications at each Olympic retrospective analysis as better tests are applied to stored samples.